Digital PCR and qPCR Market Opportunities and Challenge - Forecast to 2025
2022-05-10 13:46:36 UTC | Healthcare & Pharmaceuticals
According to the new market research report
Digital PCR and qPCR Market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
Factors
such as the rising incidence of target infectious diseases and genetic
disorders; technological advancements in PCR technologies; increasing
investments, funds, and grants; increasing use of biomarker profiling
for disease diagnostics; and successful completion of the Human Genome
Project are driving the growth of this market. However, the high
instrument costs—especially that of dPCR—and the technical limitations
of PCR have restricted their greater use.
Based on application,
the market is categorized into clinical applications (Infectious Disease
Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and
Other Clinical Applications), research applications and forensic
applications. The clinical applications segment is estimated to dominate
the qPCR applications market in 2020. The key factors driving the
market growth of cclinical applications segment include the growing
usage of qPCR in disease diagnosis, rising incidence of infectious and
genetic diseases, and growing public emphasis on early & effective
disease diagnosis & treatment.
Based on products &
services, the market is categorized into reagents and consumables,
instruments and software & services. The qPCR reagents and
consumables segment is expected to command the largest share of the qPCR
products & services market in 2020, owing to the factors such as
the expanding applications of qPCR (owing to its technological benefits
over traditional PCR, such as real-time analysis and reduced analysis
time), growing private-public funding for life science research, and the
rising number of probe-based multiplex genetic analysis procedures
(that require the analysis of low-volume gene samples).
OPPORTUNITY: Growing market penetration in emerging countries
Emerging
markets are expected to offer significant growth opportunities due to
the rising incidence of infectious and chronic diseases as well as
increasing R&D initiatives to develop innovative genomic techniques
such as qPCR and dPCR. The growth in these markets is supported by the
expansion of healthcare infrastructure, increase in healthcare
expenditure, and reducing procedural costs for qPCR and dPCR-based
disease diagnosis. Emerging countries are witnessing rapid modernization
in healthcare facilities and the expansion of healthcare
infrastructure. This factor is contributing to the growing demand for
clinical diagnostic procedures among diagnostic laboratories, which is
resulting in the increased sales of clinical qPCR and dPCR products.
CHALLENGES: Adoption and implementation of MIQE guidelines
Currently,
the use of qPCR and dPCR techniques is unregulated globally, which has
made end users reluctant to use qPCR and dPCR products in genomic
analysis and disease diagnosis. This is mainly due to a non-uniform
consensus that exists for the method by which qPCR/dPCR experiments
should be conducted to obtain quality results in a time-bound manner.
However, there have been attempts to develop guidelines that can
streamline and define the minimum requirements needed to carry a
qPCR/dPCR-based genomic procedure in a scientific manner with efficient
data generation and interpretation.
Thermo Fisher Scientific
(US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd.
(Switzerland) are the key players operating in this market. Other
prominent players are Abbott Laboratories (US), Agilent Technologies
(US), Analytik Jena AG (Switzerland), Becton Dikinson and Company (US),
bioMérieux SA (France), Danaher Corporation (US), Eppendorf (Germany),
Fluidigm Corporation (US), Merck KGaA (Germany), QIAGEN N.V.
(Netherlands), Takara Bio (Japan), Meridian Bioscience (US), Promega
Corporation (US), Enzo Life Sciences, Inc. (US), Bioneer (South Korea),
ELITech Group (France), and Quidel Corporation (US).
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
North
America accounted for the largest share of the Digital PCR and qPCR
Market, followed by Europe in 2019. The large share of the North
American regional segment can be attributed to the increased adoption of
innovative and novel genomic analysis products (including advanced qPCR
and dPCR products), availability of R&D funding for genomic
research (coupled with the robust research infrastructure in the
region), expanding use of PCR techniques in clinical diagnostics &
forensics, and early commercialization of qPCR/dPCR products compared to
other regions.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
